Adding ketamine to fentanyl fails to reduce pain in trauma
Medscape highlights UC-led research study
Medscape highlighted research led by the University of Cincinnati's Jason McMullan, MD, that found adding intranasal ketamine to fentanyl does not improve pain scores in patients with out-of-hospital trauma injuries.
The research was recently published in the Annals of Emergency Medicine.
The team conducted a randomized clinical trial of 192 patients requiring out-of-hospital pain medication for acute traumatic injuries. Participants received standard care treatment with fentanyl followed by a single intranasal dose of either 50 mg of ketamine or a placebo.
Researchers found there was no statistically significant difference between the ketamine and placebo groups, and pain over 3 hours of emergency department care did not differ at any point between the two groups.
"Although adding intranasal ketamine did not prove effective in any measured outcome, ketamine did not increase the risk of important adverse events. Importantly, we observed no difference in sedation after receiving ketamine and fentanyl, and no episodes of laryngospasm or emergence phenomenon occurred," the study authors wrote.
Featured photo at top of ketamine vial. Photo/Jennifer Fontan/iStock.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.